John R. Penrod - Concepedia

Author

John R. Penrod

Bristol-Myers Squibb (United States)

Also Known As

John Penrod, John R Penrod, John R. Penrod, Penrod, John R.

118

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Belgium)McGill University IQVIA (United Kingdom)Bristol-Myers Squibb (Germany)

About

John R. Penrod is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	967
2	Health Sciences	4	4	117
3	Business	1	1	26
4	Law	1	1	26
5	Nursing	1	1	34

John R. Penrod

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee Paul R. Fortin, John R. Penrod, Ann E. Clarke, Arthritis & Rheumatism	2002	430
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, The Lancet Oncology OncologyFour-year SurvivalImmune Checkpoint InhibitorCancer TreatmentPooled Analysis	2019	361
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial Martin Reck, Michael Schenker, Ki Hyeong Lee, European Journal of Cancer	2019	212
Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa Motasim Badri, Gary Maartens, Sundhiya Mandalia, PLoS Medicine	2005	145
Health services costs and their determinants in women with fibromyalgia. John R. Penrod, Sasha Bernatsky, Viviane Adam, PubMed	2004	133
How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies Darius Lakdawalla, John A. Romley, Yuri Sanchez, Health Affairs	2012	124
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis Matteo Giaj Levra, François-Emery Cotté, R. Corre, Lung Cancer	2019	123
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study Martin Reck, Fiona Taylor, John R. Penrod, Journal of Thoracic Oncology Checkmate 017OncologyHealth-related QualityCancer ManagementOutcomes Research	2017	106
Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction Louise Pilote, Lawrence Joseph, Patrick Bélisle, American Heart Journal Health Insurance ReformPercutaneous Coronary InterventionHealth Care DeliveryHealth PolicyCardiovascular Disease	2003	87
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes Ron Goeree, Julie Villeneuve, Jeff Goeree, Journal of Medical Economics Cancer ManagementPrognosisClinical EndpointPs Model ApproachEpidemiology Of Cancer	2016	77

Page 1